The role of omalizumab in the treatment of severe allergic rhinitis based on clinical examples from real practice

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

The prevalence of allergic rhinitis (AR) in Russia depends on the region, climate zone and occupies from 18 to 33.2% in the structure of respiratory allergic diseases. Against the background of an increase in the number of patients with respiratory allergies, a tendency towards aggravation of symptoms is noted. Thus, among patients with allergic rhinitis, 62.7% have moderate and severe forms. About 35-40% of patients, despite adequate treatment, according to the recommendations of medical specialists, do not achieve control over the symptoms of allergic rhinitis. Symptoms of allergic rhinitis, such as nasal congestion, nasal discharge, sneezing and itching, can significantly affect everyday life, quality of sleep and lead to psychological and social problems. The growing trend in the number of patients with uncontrolled symptoms of AR indicates the need to optimize approaches to therapy and implement the principles of personalized medicine in order to achieve a higher level of symptom control, increase patient compliance and satisfaction with treatment. One of the approaches that meets modern requirements for efficacy and safety in patients with uncontrolled severe symptoms of allergic rhinitis is the use of genetically engineered biological drugs. The efficacy and safety of biological drugs is confirmed by clinical examples from real practice. The article presents a series of clinical cases of severe uncontrolled symptoms of AR against the background of standard pharmacotherapy. The addition of biological drugs to standard pharmacotherapy, in particular omalizumab, allows for faster control of AR symptoms, increased treatment effectiveness and reduced need for symptomatic therapy. High efficacy and good tolerability and safety profile of omalizumab, as well as long-term experience of use in children and adults, make it an optimal choice for additional therapy of moderate-severe seasonal AR symptoms, allowing to maintain a good quality of life of patients during the palination season.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Aysa Nasunova

Russian Medical Academy of Continuous Professional Education

Хат алмасуға жауапты Автор.
Email: aysanasunova@gmail.com
ORCID iD: 0009-0006-7116-9091
SPIN-код: 9297-8223

Cand. Sci. (Med.), Teaching Assistant, Department of Allergology and Immunology

Ресей, Moscow

Natalia Nenasheva

Russian Medical Academy of Continuous Professional Education

Email: 1444031@gmail.com
ORCID iD: 0000-0002-3162-2510
SPIN-код: 3363-6170

Dr. Sci. (Med.), Professor, Head of the Department of Allergology and Immunology

Ресей, Moscow

Әдебиет тізімі

  1. Wise S. K. et al. A synopsis of guidance for allergic rhinitis diagnosis and management from ICAR 2023. The Journal of Allergy and Clinical Immunology: In Practice. 2023;11(3):773–796.
  2. Назарова Е.В., Хаитов М.Р. Особенности структуры аллергических заболеваний и спектра сенсибилизации в Российской Федерации с учетом климатогеографических особенностей регионов. Российский Аллергологический Журнал. 2024;21(4):440–450. [Nazarova E.V., Khaitov M.R. Characteristics of the allergic disorder and sensibilization spectrum distributions in the Russian Federation taking into account climatic and geographical features of the regions. Russian Journal of Allergy. 2024;21(4):440–450. (In Russ.)]. doi: 10.36691/RJA16967
  3. Gerth van Wijk R., Smits H.H. Heterogeneity in allergic rhinitis: Explained by inducible mechanistic traits? J Allergy Clin Immunol. 2021 Aug;148(2):358–360. doi: 10.1016/j.jaci.2021.06.011.
  4. WHO Collaborating Center for Asthma and Rhinitis; Bousquet J, Anto J.M., Demoly P., et al. Severe chronic allergic (and related) diseases: a uniform approach--a MeDALL--GA2LEN--ARIA position paper. Int Arch Allergy Immunol. 2012;158(3):216–31. doi: 10.1159/000332924
  5. Safia A., Elhadi U.A., Karam M., et al. A meta-analysis of the prevalence and risk of mental health problems in allergic rhinitis patients. J Psychosom Res. 2024 Sep;184:111813. doi: 10.1016/j.jpsychores.2024.111813
  6. Liu J., Zhang X., Zhao Y., Wang Y. The association between allergic rhinitis and sleep: A systematic review and meta-analysis of observational studies. PLoS One. 2020 Feb 13;15(2):e0228533. doi: 10.1371/journal.pone.0228533
  7. Wang C., Sun K., Liu K., Yu Z. Association of allergic rhinitis with persistent obstructive sleep apnea: A secondary analysis of the childhood adenotonsillectomy trial. Sleep Med. 2024 Mar;115:246–250. doi: 10.1016/j.sleep.2024.02.029
  8. Wang Q., Wang R., Li M., et al. The relationship between allergic rhinitis and attention deficit hyperactivity disorder: a systematic review and meta-analysis. PeerJ. 2024 Oct 18;12:e18287. doi: 10.7717/peerj.18287
  9. Клинические рекомендации Аллергический ринит, 2024. Ссылка на рубрикатор: https://cr.minzdrav.gov.ru/view-cr/261_2 (дата обращения: 15.04.2025). [Clinical guidelines Allergic rhinitis, 2024. Link to the rubricator: https://cr.minzdrav.gov.ru/view-cr/261_2 (date of access: 15.04.2025). (In Russ.)].
  10. Price D., Zhang Q., Kocevar V.S., et al. Effect of a concomitant diagnosis of allergic rhinitis on asthma-related health care use by adults. Clin Exp Allergy. 2005 Mar;35(3):282–7. doi: 10.1111/j.1365-2222.2005.02182.x
  11. Neto H.J., Rosario N.A., Westphal G.L., et al. Allergic conjunctivitis in asthmatic children: as common as underreported. Ann Allergy Asthma Immunol. 2010 Nov;105(5):399–400. doi: 10.1016/j.anai.2010.08.020
  12. Van Bulck P., Cools L., Soumya M.S., et al. A multicenter real-life study on the multiple reasons for uncontrolled allergic rhinitis. Int Forum Allergy Rhinol. 2021 Oct;11(10):1452-1460. doi: 10.1002/alr.22808 [Epub 2021 Jul 14. Erratum in: Int Forum Allergy Rhinol. 2022 Aug;12(8):1081]. doi: 10.1002/alr.23021
  13. Menditto E., Costa E., Midao L., et al.; MASK group. Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. Clin Exp Allergy. 2019 Apr;49(4):442–460. doi: 10.1111/cea.13333
  14. Hellings P.W., Fokkens W.J., Bachert C., et al.; ARIA and EPOS working groups. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis - A EUFOREA-ARIA-EPOS-AIRWAYS ICP statement. Allergy. 2017 Sep;72(9):1297–1305. doi: 10.1111/all.13162
  15. Yamani I., Bu Saeed K., Alsulami A., et al. Efficacy of Biologic Therapies in the Management of Allergic Rhinitis: A Systematic Review. Cureus. 2024 Oct 14;16(10):e71408. doi: 10.7759/cureus.71408
  16. Okubo K., Ogino S., Nagakura T., Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int. 2006 Dec;55(4):379–86. doi: 10.2332/allergolint.55.379
  17. Casale T.B., Condemi J., LaForce C., et al.; Omalizumab Seasonal Allergic Rhinitis Trail Group. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA. 2001 Dec 19;286(23):2956–67. doi: 10.1001/jama.286.23.2956
  18. Pfaar O., Gehrt F., Li H., et al. Anti-IgE: A treatment option in allergic rhinitis? Allergologie Select. 2021;5:119–127. doi: 10.5414/alx02205e
  19. Павлова К.С., Куличенко Д.С., Курбачева О.М. и др. Омализумаб в лечении сезонных обострений тяжeлого аллергического ринита. Российский Аллергологический Журнал. 2022;19(2):164–174. [Pavlova K.S., Kulichenko D.S., Kurbacheva O.M., et al. Omalizumab in the severe exacerbations of seasonal allergic rhinitis. Russian Journal of Allergy. 2022;19(2):164–174. (In Russ.)]. doi: 10.36691/RJA1539
  20. Chervinsky P., Casale T., Townley R., et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003 Aug;91(2):160–7. doi: 10.1016/S1081-1206(10)62171-0
  21. Zhang Y., Xi L., Gao Y., et al. Omalizumab is effective in the preseasonal treatment of seasonal allergic rhinitis. Clin Transl Allergy. 2022 Jan 4;12(1):e12094. doi: 10.1002/clt2.12094
  22. Casale T.B., Bernstein I.L., Busse W.W., et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol. 1997 Jul;100(1):110–121. doi: 10.1016/s0091-6749(97)70202-1
  23. Fox J.A., Hotaling T.E., Struble C., et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther. 1996 Nov;279(2):1000–1008.
  24. MacGlashan D.W. Jr., Bochner B.S., Adelman D.C., et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. Journal of Immunology (Baltimore, Md. : 1950). 1997 Feb;158(3):1438-1445.
  25. Saini S.S., MacGlashan D.W. Jr., Sterbinsky S.A., et al. Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol (Baltimore, Md.: 1950). 1999 May;162(9):5624–5630.
  26. Lin H., Boesel K.M., Griffith D.T., et al. Omalizumab rapidly decreases nasal allergic response and FcepsilonRI on basophils. J Allergy Clin Immunol. 2004 Feb;113(2):297–302. doi: 10.1016/j.jaci.2003.11.044
  27. Beck L.A., Marcotte G.V., MacGlashan D., et al. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol. 2004 Sep;114(3):527–530. doi: 10.1016/j.jaci.2004.06.032
  28. Tsabouri S., Tseretopoulou X., Priftis K., Ntzani E.E. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. The Journal of Allergy and Clinical immunology. In Practice. 2014 May-Jun;2(3):332-40.e1. doi: 10.1016/j.jaip.2014.02.001
  29. Емельянов А.В., Ильина Н.И., Карнеева О.В. и др. Нерешенные вопросы ведения пациентов с тяжелым аллергическим ринитом и полипозным риносинуситом. Возможности анти-IGE-терапии. 2020;19(3):88–99. [Emel’yanov A.V., Il’ina N.I., Karneeva O.V., Karpishchenko S.A., Kim I. A., Kurbacheva O. M., Nenasheva N. M., Obukhova O. V., Svistushkin V. M., Ukhanova O. P. Unresolved issues of management of patients with severe allergic rhinitis and nasal polyposis. The possibilities of anti-IgE therapy. Rossiiskaya otorinolaringologiya. 2020;19(3):88–99. (In Russ.)]. https://doi.org/10.18692/1810-4800-2020-3-88-99
  30. Yu C., Wang K., Cui X., et al. Clinical Efficacy and Safety of Omalizumab in the Treatment of Allergic Rhinitis: A Systematic Review and Meta-analysis of Randomized Clinical Trials. Am J Rhinol Allergy. 2020 Mar;34(2):196–208. doi: 10.1177/1945892419884774
  31. Bayar Muluk N., Bafaqeeh S.A., Cingi C. Anti-IgE treatment in allergic rhinitis. Int J Pediatr Otorhinolaryngol. 2019 Dec;127:109674. doi: 10.1016/j.ijporl.2019.109674
  32. Kuehr J., Brauburger J., Zielen S., et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002 Feb;109(2):274–80. doi: 10.1067/mai.2002.121949
  33. Goto T., Miwa T., Hashimoto K., et al. Evaluating the Efficacy of Omalizumab in Severe Cedar Seasonal Allergic Rhinitis in Japan. Cureus. 2024 Jul 2;16(7):e63714. doi: 10.7759/cureus.63714
  34. Kamin W., Kopp M.V., Erdnuess F., et al. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol. 2010 Feb;21(1 Pt 2):e160–5. doi: 10.1111/j.1399-3038.2009.00900.x
  35. Cavaliere C., Begvarfaj E., Incorvaia C., et al. Long-term omalizumab efficacy in allergic rhinitis. Immunol Lett. 2020 Nov;227:81–87. doi: 10.1016/j.imlet.2020.08.002
  36. Vignola A.M., Humbert M., Bousquet J., et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy. 2004 Jul;59(7):709–717. doi: 10.1111/j.1398-9995.2004.00550.x
  37. Crystal-Peters J., Neslusan C., Crown W.H., Torres A. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol. 2002 Jan;109(1):57–62. doi: 10.1067/mai.2002.120554
  38. Guntern P., Eggel A. Past, present, and future of anti-IgE biologics. Allergy. 2020 Oct;75(10):2491–2502. doi: 10.1111/all.14308
  39. Nagakura T., Ogino S., Okubo K, et al. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy. 2008 Feb;38(2):329–337. doi: 10.1111/j.1365-2222.2007.02894.x
  40. Cox L., Lieberman P., Wallace D., et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol. 2011 Jul;128(1):210–212. doi: 10.1016/j.jaci.2011.04.010
  41. Bousquet J., Khaltaev N., Cruz A.A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008 Apr;63 Suppl 86:8–160. doi: 10.1111/j.1398-9995.2007.01620.x
  42. Holgate S., Buhl R., Bousquet J., et al. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update. Respir Med. 2009 Aug;103(8):1098–1113. doi: 10.1016/j.rmed.2009.03.008
  43. Deniz Y.M., Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin Rev Allergy Immunol. 2005 Aug;29(1):31–48. doi: 10.1385/criai:29:1:031
  44. Cruz A.A., Lima F., Sarinho E., et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007 Feb;37(2):197–207. doi: 10.1111/j.1365-2222.2007.02650.x
  45. Watanabe N., Katakura K., Kobayashi A., et al. Protective immunity and eosinophilia in IgE-deficient SJA/9 mice infected with Nippostrongylus brasiliensis and Trichinella spiralis. Proc Natl Acad Sci U S A. 1988 Jun;85(12):4460–4462. doi: 10.1073/pnas.85.12.4460
  46. Amiri P., Haak-Frendscho M., Robbins K., et al. Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J Exp Med. 1994 Jul;180(1):43–51. doi: 10.1084/jem.180.1.43
  47. Long A., Rahmaoui A., Rothman K.J., et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol. 2014 Sep;134(3):560–567.e4. doi: 10.1016/j.jaci.2014.02.007

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2025